Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report

Figure 1 High power (200 ×) haematoxylin and eosin stained section showing neutrophilic crypt abscesses, no viral inclusion bodies seen.

Figure 2 Colonoscopy prior to infliximab showing diffuse moderate inflammation in the sigmoid colon characterized by erosions, erythema, friability, granularity and a loss of vascularity.

Figure 3 Immune-related adverse event timeline, showing type and severity of toxicity and time points of treatment intervention. irAE: Immune-related adverse event.